Skip to content
Screener

Nuvation Bio NUVB Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$785K-39.8%
Immunome logo
ImmunomeIMNM
$2.83M-32.1%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
10.2%0.0pp
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$370K+208%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
11.1%+0.1pp
Summit Therapeutics logo
Summit TherapeuticsSMMT
$19.4M+205%

Other financials

Income statement

See full
Revenue$31.7M+556%
Gross profit$9.8M+1,340%
Operating income-$51.0M+19.7%
Net income-$62.8M-6.5%
EPS (diluted)-$0.18-5.9%

Balance sheet

See full
Cash & equivalents$258.6M+4.3%
Total debt$9.5M-83.5%
Total equity$253.9M-31.9%
Total assets$744.5M+15.0%

Cash flow

See full
Operating cash flow-$43.0M+10.8%
CapEx$254.0K+40.3%
Free cash flow-$43.2M+10.6%

Valuation

See full
Market cap$2.15B+168%
Enterprise value$1.9B+211%
P/S12.6×-43.1×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-81%-39.4pp
Net margin-88.2%-42.7pp
FCF margin-75.7%-36.6pp

Returns & leverage

See full
Return on equity-47.8%-9.8pp
Debt / equity-0.1×
Current ratio8.4×-1.0×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:55 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336646
Line itemJune 30, 2026December 31, 2025
Total current assets726,432571,519
Property and equipment, net of accumulated depreciation of $1,331 and $1,184, respectively715564
Intangible assets, net of accumulated amortization of $2,777 and $1,856, respectively10,29211,214
Operating lease right-of-use assets3,2403,918
Other non-current assets3,8247,607
Total assets$744,503$594,822
Liabilities and stockholders’ equity
Current liabilities:

Item 1. Financial Statements.

FAQ

What is Nuvation Bio's operating lease ROU assets?
Nuvation Bio (NUVB) reported operating lease ROU assets of $3.24M in Q2 2026.
How has Nuvation Bio's operating lease ROU assets changed year-over-year?
Nuvation Bio's operating lease ROU assets decreased by 30.2% year-over-year, from $4.64M to $3.24M.
What is the long-term trend for Nuvation Bio's operating lease ROU assets?
Over 4 years (2021 to 2025), Nuvation Bio's operating lease ROU assets has grown at a 8.1% compound annual growth rate (CAGR), from $2.87M to $3.92M.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.

Ask your AI about Nuvation Bio's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude